Addressing hepatitis delta in primary care practices in the US: a narrative review

References

• He LF, Ford E, Purcell RH, et al. The size of the hepatitis delta agent. J Med Virol. 1989;27(1):31–33. doi:10.1002/jmv.1890270107.
   PubMed Web of Science ®Google Scholar
• Lempp FA, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016;13(10):580–589. doi:10.1038/nrgastro.2016.126.
   PubMed Web of Science ®Google Scholar
• Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70(9):1782–1794. doi:10.1136/gutjnl-2020-323888.
   PubMed Web of Science ®Google Scholar
• Lucifora J, Delphin M. Current knowledge on hepatitis delta virus replication. Antiviral Res. 2020;179:104812. doi:10.1016/j.antiviral.2020.104812.
   PubMed Web of Science ®Google Scholar
• Rizzetto M. Hepatitis D virus: introduction and epidemiology. Cold Spring Harb Perspect Med. 2015;5(7):a021576. doi:10.1101/cshperspect.a021576.
   PubMed Web of Science ®Google Scholar
• Sellier PO, Maylin S, Brichler S, et al. Hepatitis B virus-hepatitis D virus mother-to-child co-transmission: a retrospective study in a developed country. Liver Int. 2018;38(4):611–618. doi:10.1111/liv.13556.
   PubMed Web of Science ®Google Scholar
• Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring Harb Perspect Med. 2014;4(11):a021550. doi:10.1101/cshperspect.a021550.
   PubMed Web of Science ®Google Scholar
• Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf). 2019;7(4):231–245. doi:10.1093/gastro/goz023.
   PubMed Web of Science ®Google Scholar
• Alfaiate D, Clément S, Gomes D, et al. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol. 2020;73(3):533–539. doi:10.1016/j.jhep.2020.02.030.
   PubMed Web of Science ®Google Scholar
• Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629–1638. doi:10.1053/j.gastro.2009.01.052.
   PubMed Web of Science ®Google Scholar
• Muhammad H, Tehreem A, Hammami MB, et al. Hepatitis D virus and liver transplantation: indications and outcomes. World J Hepatol. 2021;13(3):291–299. doi:10.4254/wjh.v13.i3.291.
   PubMed Web of Science ®Google Scholar
• Patel EU, Thio CL, Boon D, et al. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011-2016. Clin Infect Dis. 2019;69(4):709–712. doi:10.1093/cid/ciz001.
   PubMed Web of Science ®Google Scholar
• Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586–592. doi:10.1016/j.jhep.2015.04.025.
   PubMed Web of Science ®Google Scholar
• Safaie P, Razeghi S, Rouster SD, et al. Hepatitis D diagnostics: utilization and testing in the United States. Virus Res. 2018;250:114–117. doi:10.1016/j.virusres.2018.03.013.
   PubMed Web of Science ®Google Scholar
• Glynn M, Cohen C, Gish RG, et al. Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S. Hepatol Commun. 2023;7(7):e00168. doi:10.1097/hc9.0000000000000168.
   PubMed Web of Science ®Google Scholar
• Burman BE, Mukhtar NA, Toy BC, et al. Hepatitis B management in vulnerable populations: gaps in disease monitoring and opportunities for improved care. Dig Dis Sci. 2014;59(1):46–56. doi:10.1007/s10620-013-2870-z.
   PubMed Web of Science ®Google Scholar
• Wu Y, Johnson KB, Roccaro G, et al. Poor adherence to AASLD guidelines for chronic hepatitis B management and treatment in a large academic medical center. Am J Gastroenterol. 2014;109(6):867–875. doi:10.1038/ajg.2014.72.
   PubMed Web of Science ®Google Scholar
• Ye Q, Kam LY, Yeo YH, et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol. 2022;76(1):63–74. doi:10.1016/j.jhep.2021.08.019.
   PubMed Web of Science ®Google Scholar
• Palom A, Rando-Segura A, Riveiro-Barciela M, et al. Low adherence to guidelines recommendation for testing hepatitis D in HBsAg positive patients leads to a high rate of undiagnosis. Hepatology. 2021;74:148A–149A.
   PubMed Web of Science ®Google Scholar
• Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523–532. doi:10.1016/j.jhep.2020.04.008.
   PubMed Web of Science ®Google Scholar
• Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512–521. doi:10.1136/gutjnl-2018-316601.
   PubMed Web of Science ®Google Scholar
• Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677–1687. doi:10.1093/infdis/jiz633.
   PubMed Web of Science ®Google Scholar
• Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol. 2015;7(18):2127–2132. doi:10.4254/wjh.v7.i18.2127.
   PubMed Web of Science ®Google Scholar
• Krsak M, Montague BT, Trowbridge P, et al. Opioid use and chronic infections: the value of addressing the syndemic in correctional settings via telemedicine guidance and broader use of long-acting medications. J Infect Dis. 2020;222(S5): s 486–S493. doi:10.1093/infdis/jiaa001.
   Google Scholar
• Da BL, Rahman F, Lai WC, et al. Risk factors for delta hepatitis in a North American cohort: who should be screened? Am J Gastroenterol. 2021;116(1):206–209. doi:10.14309/ajg.0000000000000954.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800.
   PubMed Web of Science ®Google Scholar
• Miao Z, Pan Q. Revisiting the estimation of hepatitis D global prevalence. J Hepatol. 2020;73(5):1279–1280. doi:10.1016/j.jhep.2020.05.019.
   PubMed Web of Science ®Google Scholar
• Papatheodoridi M, Papatheodoridis GV. Is hepatitis delta underestimated? Liver Int. 2021;41(S1):38–44. doi:10.1111/liv.14833.
   PubMedGoogle Scholar
• Stockdale AJ, Kreuels B, Henrion MRY, et al. Hepatitis D prevalence: problems with extrapolation to global population estimates. Gut. 2020;69(2):396–397. doi:10.1136/gutjnl-2018-317874.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis D fact sheet. [Internet]. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-d.
   Google Scholar
• Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477–483. doi:10.15585/mmwr.mm7113a1.
   PubMed Web of Science ®Google Scholar
• Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and testing for hepatitis B virus infection: CDC recommendations - United States, 2023. MMWR Recomm Rep. 2023;72(1):1–25. doi:10.15585/mmwr.rr7201a1.
   Google Scholar
• Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018;67(1):1–31. doi:10.15585/mmwr.rr6701a1.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi:10.1007/s12072-015-9675-4.
   PubMed Web of Science ®Google Scholar
• Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32(3):228–236. doi:10.1055/s-0032-1323628.
   PubMed Web of Science ®Google Scholar
• Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int. 2011;31(1):7–21. doi:10.1111/j.1478-3231.2010.02320.x.
   Google Scholar
• Usai C, Gill US, Riddell AC, et al. Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus. Aliment Pharmacol Ther. 2022;55(8):978–993. doi:10.1111/apt.16807.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Postexposure prophylaxis of hepatitis B. MMWR Morb Mortal Wkly Rep. 1984;33(21):285–290.
   PubMedGoogle Scholar
• Liu Y, Wang M, Yao S, et al. Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus. Hepatol Res. 2016;46(3):E181–188. doi:10.1111/hepr.12525.
   PubMed Web of Science ®Google Scholar
• Chilaka VN, Konje JC. Viral hepatitis in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2021;256:287–296. doi:10.1016/j.ejogrb.2020.11.052.
   PubMed Web of Science ®Google Scholar
• Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–386. doi:10.1002/hep.27837.
   PubMed Web of Science ®Google Scholar
• Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–2334. doi:10.1056/NEJMoa1508660.
   PubMed Web of Science ®Google Scholar
• Asselah T, Loureiro D, Tout I, et al. Future treatments for hepatitis delta virus infection. Liver Int. 2020;40(S1):54–60. doi:10.1111/liv.14356.
   PubMedGoogle Scholar
• Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126(7):1740–1749. doi:10.1053/j.gastro.2004.03.017.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydìn C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322–331. doi:10.1056/NEJMoa0912696.
   PubMed Web of Science ®Google Scholar
• Heidrich B, Yurdaydın C, Kabaçam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60(1):87–97. doi:10.1002/hep.27102.
   PubMed Web of Science ®Google Scholar
• Etzion O, Hamid SS, Lurie Y, et al. PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. J Hepatol. 2019;70(1):E32. doi:10.1016/s0618-8278(19)30058-1.
   Web of Science ®Google Scholar
• Chan HLY, Ahn SH, Chang TT, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (Lira-B). J Hepatol. 2016;64(5):1011–1019. doi:10.1016/j.jhep.2015.12.018.
   PubMed Web of Science ®Google Scholar
• Hepcludex. Summary of product characteristics. Gilead Sciences Ireland UC. 2021.
   Google Scholar
• Wedemeyer H, Schöneweis K, Bogomolov P, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2022;23(1):117–129. doi:10.1016/s1473-3099(22)00318-8.
   PubMed Web of Science ®Google Scholar
• Asselah T, Arama S, Bogomolov P, et al. Safety and efficacy of bulevirtide monotherapy and in combination with peginterferon alpha-2a in patients with chronic hepatitis delta: 24 weeks interim data of MYR204 phase 2b study. J Hepatol. 2021;75(2):S291.
   Google Scholar
• Wedemeyer H, Aleman S, Andreone P, et al. Bulevirtide monotherapy at low and high doses in patients with chronic hepatitis delta: 24-week interim data of the phase 3 MYR301 study. J Hepatol. 2021;75:S294–S803.
   Google Scholar
• Wedemeyer H, Aleman S, Brunetto M, et al. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel design study. Poster Session Presented at: The International Liver Congress. London, UK: European Association for the Study of the Liver; 2022.
   Google Scholar
• Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15(10):1167–1174. doi:10.1016/S1473-3099(15)00074-2.
   PubMed Web of Science ®Google Scholar
• Eiger announces both lonafarnib-based treatments in pivotal phase 3 D-LIVR trial in hepatitis delta virus (HDV) achieved statistical significance against placebo in composite primary endpoint. CISION PR Newswire; 2022.
   Google Scholar